Renato Dela Cruz, MD
Internal Medicine · Martins Ferry, OHNPI 1174523641
Payments from drug & device makers
Across 970 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$3K
- Bayer$2K
- Pfizer$1K
- Novo Nordisk$934
- Merck$755
- plus $10K from 51 others
What the payments were for
- Speaking & faculty fees$110%
- Food & beverage$20,006100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,061 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 433 | $337,182 |
| EliquisApixaban | 622 | $269,766 |
| OzempicSemaglutide | 246 | $266,179 |
| KerendiaFinerenone | 193 | $160,887 |
| TrulicityDulaglutide | 130 | $133,412 |
| JardianceEmpagliflozin | 183 | $122,470 |
| XareltoRivaroxaban | 174 | $111,240 |
| JanuviaSitagliptin Phosphate | 121 | $66,317 |
| EntrestoSacubitril/Valsartan | 111 | $66,089 |
| NuplazidPimavanserin Tartrate | 26 | $64,625 |
| Austedo XrDeutetrabenazine | 23 | $56,436 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $49,181 |
| LinzessLinaclotide | 56 | $42,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $40,184 |
| Xigduo XrDapaglifloz Propaned/Metformin | 49 | $39,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $3,248 | $388,355541 claims |
| Novo NordiskOzempic, Rybelsus | $934 | $287,449260 claims |
| PfizerEliquis | $1,088 | $269,766622 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $159 | $166,258261 claims |
| BayerKerendia | $1,618 | $160,887193 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $545 | $146,282188 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $417 | $144,740142 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $474 | $67,368111 claims |
| MerckJanuvia | $755 | $66,317121 claims |
| NovartisEntresto | $485 | $66,089111 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $220 | $56,43623 claims |
| AbbVieLinzess | $2,711 | $42,55856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Martins Ferry
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.